PTC Therapeutics Inc (PTCT) — Cash Flow-to-Debt Ratio
PTC Therapeutics Inc (PTCT) has a Cash Flow-to-Debt Ratio of -0.01x as of December 2025, meaning its operating cash flow of $-34.27 Million could theoretically repay 0% of its total liabilities ($3.12 Billion) in one year. See PTCT cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PTC Therapeutics Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for PTC Therapeutics Inc across 15 annual periods. Also explore PTCT net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for PTC Therapeutics Inc (2011–2025)
Year-by-year debt coverage analysis for PTC Therapeutics Inc. For market capitalisation and broader financial context, see PTC Therapeutics Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | $711.20 Million | $3.12 Billion | ▲ +694.0% |
| 2024 | -0.04x | $-107.69 Million | $2.80 Billion | ▲ +34.2% |
| 2023 | -0.06x | $-158.42 Million | $2.71 Billion | ▲ +66.4% |
| 2022 | -0.17x | $-356.65 Million | $2.05 Billion | ▼ -33.9% |
| 2021 | -0.13x | $-251.33 Million | $1.94 Billion | ▼ -15.4% |
| 2020 | -0.11x | $-194.07 Million | $1.73 Billion | ▼ -17.3% |
| 2019 | -0.10x | $-98.64 Million | $1.03 Billion | ▼ -166.4% |
| 2018 | -0.04x | $-27.64 Million | $768.50 Million | ▲ +15.9% |
| 2017 | -0.04x | $-10.06 Million | $235.22 Million | ▲ +93.8% |
| 2016 | -0.69x | $-103.57 Million | $149.76 Million | ▲ +61.3% |
| 2015 | -1.79x | $-124.34 Million | $69.57 Million | ▼ -8.4% |
| 2014 | -1.65x | $-57.27 Million | $34.75 Million | ▲ +46.0% |
| 2013 | -3.05x | $-46.92 Million | $15.36 Million | ▼ -105.7% |
| 2012 | -1.49x | $-47.93 Million | $32.27 Million | ▼ -1922.4% |
| 2011 | -0.07x | $-20.77 Million | $282.75 Million | — |